Subsequently, the ORIENT-11 study (24) continued the treatment paradigm of immunotherapy combined with chemotherapy by applying a selective anti-PD-1 monoclonal antibody, sintilimab, to exert anti-tumor effects by blocking the PD-1/PD-L1 interaction to reactivate immune cells, and showed that the addition of sintilimab to standard chemotherapy significantly prolonged median PFS by 4.2 months (9.2 vs. 5.0 months), which was similar to the results of the Keynote-189 study (median PFS prolongation of 4.1 months, 9.0 vs. 4.9 months). This evidence concerns the gene CD274 and neoplasm.